Results for primary outcome measures in preterm infants receiving either oral vitamin A supplementation or placebo
| Vitamin A (n=77) | Placebo (n=77) | RR (95% CI) | p Value | |
| Survived | 52 (68%) | 48 (62%) | 1.12 (0.81 to 1.61) | 0.50 |
| CLD at 28 days in survivors | 43 (83%) | 42 (88%) | 0.84 (0.57 to 1.46) | 0.86 |
| Survived without CLD at 28 days | 9 (12%) | 6 (8%) | 1.23 (0.71 to 1.75) | 0.41 |
| CLD at 36 weeks in survivors | 40 (77%) | 37 (77%) | 1.0 (0.67 to 1.64) | 0.98 |
| Survived without CLD at 36 weeks | 12 (16%) | 11 (14%) | 1.05 (0.65 to 1.52) | 0.82 |
| Median (IQR) time ventilated (days) | 14 (4–24) | 15 (7–33) | — | 0.21 |
| Pulmonary haemorrhage | 5 (6%) | 11 (14%) | 0.60 (0.27 to 1.10) | 0.13 |
| Pneumothorax | 11 (14%) | 17 (22%) | 0.75 (0.44 to 1.15) | 0.24 |
| Treatment for retinopathy | 6 (8%) | 6 (8%) | 1.0 (0.50 to 1.58) | 0.98 |
| Survived without significant retinopathy | 45 (57%) | 45 (53%) | 1.02 (0.74 to 1.44) | 0.92 |
| PDA | 17 (22%) | 16 (21%) | 1.12 (0.74 to 1.59) | 0.84 |
| NEC | 9 (12%) | 7 (9%) | 1.14 (0.66 to 1.66) | 0.58 |
| Survived without significant IVH | 48 (62%) | 41 (54%) | 1.19 (0.86 to 1.68) | 0.29 |
| Median (IQR) number of sepsis episodes | 1 (0–2) | 1 (0–2) | 0.89 | |
| Vomiting | 1 (1%) | 5 (6%) | 0.32 (0.06 to 1.11) | 0.10 |
| Seizures | 15 (19%) | 20 (26%) | 0.82 (0.52 to 1.20) | 0.38 |
CLD, chronic lung disease; IQR, interquartile range; PDA, patent ductus arteriosus; NEC, necrotising enterocolitis; IVH, intraventricular haemorrhage.